ENVUE MEDICAL NEW (FEED) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FEED SEC filings page.
ENVUE MEDICAL INC NEW (FEED) reported $1.9M in revenue over the twelve months to Jun 30, 2026, down 17.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sales stayed flat while costs surged, leaving operations funded more by financing than by customer revenue.
The 2025 balance-sheet reset is not an operating turnaround: total assets jumped to$41.1M while revenue was essentially unchanged at$2.6M . Operating cash flow remained negative at-$9.4M while financing cash flow supplied$12.8M , so expansion was funded externally rather than by operating cash generation.
Gross margin fell from
Despite the larger asset base, near-term liquidity tightened: the current ratio fell from 1.2x in FY2024 to 1.1x in FY2025, leaving only a narrow cushion between current assets and current liabilities. Reported liquidity equaled 5.4 months of the latest annual operating outflow, while liabilities were
Financial Health Signals
We are recalculating ENVUE MEDICAL INC NEW's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
ENVUE MEDICAL INC NEW scores -4.82, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $90.5M against total assets of $41.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ENVUE MEDICAL INC NEW passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
ENVUE MEDICAL INC NEW reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ENVUE MEDICAL INC NEW generated $239K in revenue in Q2 2026. This represents a decrease of 51.6% from the same quarter a year earlier. Against the prior quarter it is down 63.4%.
ENVUE MEDICAL INC NEW's EBITDA was -$5.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
ENVUE MEDICAL INC NEW reported a net loss of $4.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
ENVUE MEDICAL INC NEW recorded an outflow of $2.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
ENVUE MEDICAL INC NEW held $1.1M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
ENVUE MEDICAL INC NEW's quarterly ROE was -15.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.0 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ENVUE MEDICAL INC NEW invested $510K in research and development in Q2 2026. This represents a decrease of 49.8% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
ENVUE MEDICAL INC NEW invested $27K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 575.0% from the same quarter a year earlier. Against the prior quarter it is up 58.8%.
Not reported for Q2 2026.
FEED Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $239K-51.6% | $653K-36.3% | $312K-29.7% | $722K+92.0% | $494K-39.5% | $1.0M+11.3% | $444K-62.3% | $376K-17.9% |
| Cost of Revenue | $505K-4.5% | $708K+7.9% | $682K+323.6% | $533K+119.3% | $529K+36.0% | $656K+155.3% | $161K-63.4% | $243K+122.9% |
| Gross Profit | -$266Kn/m | -$55K-114.9% | -$370K-230.7% | $189K+42.1% | -$35K-108.2% | $369K-44.4% | $283K-61.6% | $133K-61.9% |
| R&D Expenses | $510K-49.8% | $468K-11.7% | -$5K-98.6% | $221K-11.2% | $1.0M+443.3% | $530K+338.0% | $352K+467.7% | $249K+654.5% |
| SG&A Expenses | $4.7M+60.6% | $3.2M+88.5% | $3.3M+153.3% | $2.2M+159.4% | $2.9M+219.7% | $1.7M+52.2% | $1.3M-5.5% | $854K-13.4% |
| Operating Income | -$5.5Mn/m | -$3.7Mn/m | -$14.8Mn/m | -$2.2Mn/m | -$4.0Mn/m | -$1.9Mn/m | -$1.4Mn/m | -$970Kn/m |
| EBITDA | -$5.3Mn/m | -$3.5Mn/m | -$14.6M | -$2.0Mn/m | -$3.6M | -$1.8M | N/A | -$970Kn/m |
| Interest Expense | $30K-79.2% | $36K-32.1% | N/A | $53K+60.6% | $144K+323.5% | $53K+55.9% | $34K+3.0% | $33K-5.7% |
| Income Tax | -$2K-103.2% | $33K+120.0% | -$419K-8480.0% | $35K+1066.7% | $62K+1450.0% | $15K+114.3% | $5K-54.5% | $3K0.0% |
| Net Income | -$4.9Mn/m | -$3.8Mn/m | -$12.9Mn/m | $510Kn/m | -$4.0Mn/m | -$1.9Mn/m | -$1.4Mn/m | -$998Kn/m |
| EPS (Basic) | -$1.98 | -$6.88 | -$20.00 | -$0.91 | -$1.03 | -$29.90 | -$5.35 | -$3.56 |
| EPS (Diluted) | -$1.98 | -$6.88 | -$20.00 | -$0.91 | -$1.03 | -$29.90 | -$5.35 | -$3.56 |
| Diluted Shares (Avg) | 6M | 3M | N/A | 858,434 | 484,566 | 62,615 | N/A | 280,318 |
FEED Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.4M-25.4% | $39.9M-9.6% | $41.1M+1033.2% | $54.4M+1061.5% | $51.5M+803.8% | $44.1M+607.4% | $3.6M-45.6% | $4.7M-36.4% |
| Current Assets | $4.8M-30.1% | $6.2M+60.6% | $7.3M+118.3% | $10.0M+128.8% | $6.9M+28.0% | $3.9M-35.1% | $3.3M-48.7% | $4.4M-38.9% |
| Cash & Equivalents | $1.1M-73.1% | $2.2M+291.4% | $4.2M+461.7% | $7.0M+432.6% | $4.0M+85.7% | $571K-78.9% | $752K-77.1% | $1.3M-65.5% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $2.6M+17.0% | $2.3M+12.2% | $2.3M+6.7% | $2.2M-0.3% | $2.2M-9.3% | $2.0M-22.0% | $2.2M-19.8% | $2.3M-29.2% |
| Accounts Receivable | $205K+78.3% | $332K-7.3% | $289K+194.9% | $252K-56.6% | $115K-76.5% | $358K-0.6% | $98K-69.2% | $580K+1712.5% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $29.1M-24.7% | $29.1M-14.2% | $29.1M | $38.6M | $38.6M | $33.9M | N/A | N/A |
| Total Liabilities | $7.6M-30.5% | $7.9M-6.8% | $7.6M+154.1% | $11.9M+324.2% | $11.0M+285.5% | $8.4M+208.7% | $3.0M+11.8% | $2.8M+5.2% |
| Current Liabilities | $7.3M+11.6% | $6.9M-16.3% | $6.7M+144.7% | $11.6M+361.9% | $6.5M+156.0% | $8.2M+237.9% | $2.7M+10.9% | $2.5M+5.4% |
| Non-Current Liabilities | $342K-92.3% | $991K+330.9% | $967K+245.4% | $275K-4.8% | $4.5M+1392.3% | $230K-24.3% | $280K+20.7% | $289K+3.6% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $1.3M | N/A | N/A |
| Total Equity | $30.8M-24.0% | $32.0M-10.3% | $33.5M+5242.4% | $42.5M+2168.4% | $40.5M+1324.7% | $35.7M+918.1% | $627K-84.3% | $1.9M-60.1% |
| Retained Earnings | -$124.4Mn/m | -$112.1Mn/m | -$90.5Mn/m | -$76.9Mn/m | -$76.0Mn/m | -$72.3Mn/m | -$69.8Mn/m | -$68.4Mn/m |
FEED Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7Mn/m | -$4.3Mn/m | -$2.7Mn/m | -$2.0Mn/m | -$3.4Mn/m | -$1.3Mn/m | -$548Kn/m | -$836Kn/m |
| Depreciation & Amortization | $219K-39.8% | $217K+1105.6% | $258Kn/m | $257Kn/m | $364K | $18K | $0n/m | $0n/m |
| Capital Expenditures | $27K+575.0% | $17K+240.0% | $23Kn/m | $28Kn/m | $4K+100.0% | $5K+400.0% | $0n/m | $0n/m |
| Free Cash Flow | -$2.7Mn/m | -$4.3Mn/m | -$2.7Mn/m | -$2.0Mn/m | -$3.4Mn/m | -$1.3Mn/m | -$548Kn/m | -$836Kn/m |
| Investing Cash Flow | -$27Kn/m | -$17K-111.9% | -$23Kn/m | -$28Kn/m | -$4Kn/m | $143Kn/m | $0n/m | $0n/m |
| Financing Cash Flow | $1.6M-76.7% | $2.3M+122.9% | -$34Kn/m | $4.9Mn/m | $6.8M | $1.1M | $0n/m | -$27K-100.6% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
FEED Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -111.3% | -8.4%-44.4pp | -118.6% | 26.2%-9.2pp | -7.1%-59.5pp | 36.0%-36.1pp | 63.7%+1.1pp | 35.4%-40.8pp |
| Operating Margin | -2290.4% | -568.3% | -4748.1% | -311.2% | -804.9% | -180.7% | -308.6% | -258.0% |
| Net Margin | -2049.8% | -585.3% | -4119.2% | 70.6% | -803.8% | -182.6% | -322.3% | -265.4% |
| Return on Equity | -15.9%-6.1pp | -11.9%-6.7pp | -38.4%+189.9pp | 1.2%+54.5pp | -9.8%+14.4pp | -5.3%+11.5pp | -228.2%-207.8pp | -53.3%-37.8pp |
| Return on Assets | -12.8%-5.0pp | -9.6%-5.3pp | -31.3%+8.2pp | 0.9%+22.3pp | -7.7%+4.4pp | -4.2%+5.2pp | -39.4%-27.2pp | -21.3%-11.4pp |
| Current Ratio | 0.66-0.4x | 0.90+0.4x | 1.09-0.1x | 0.86-0.9x | 1.05-1.1x | 0.47-2.0x | 1.22-1.4x | 1.74-1.3x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 0.04 | N/A | N/A |
| Liabilities-to-Equity | 0.250.0x | 0.250.0x | 0.23-4.6x | 0.28-1.2x | 0.27-0.7x | 0.24-0.5x | 4.79+4.1x | 1.50+0.9x |
| Asset Turnover | 0.010.0x | 0.020.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.1x | 0.02-0.1x | 0.12-0.1x | 0.080.0x |
| FCF Margin | -1137.2% | -662.9% | -865.1% | -276.7% | -685.6% | -131.5% | -123.4% | -222.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Where ENVUE MEDICAL INC NEW Ranks
Frequently Asked Questions
What is ENVUE MEDICAL INC NEW's annual revenue?
ENVUE MEDICAL INC NEW (FEED) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ENVUE MEDICAL INC NEW's revenue growing?
ENVUE MEDICAL INC NEW (FEED) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.
Is ENVUE MEDICAL INC NEW profitable?
No, ENVUE MEDICAL INC NEW (FEED) reported a net loss of $21.1M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $18.2M.
What is ENVUE MEDICAL INC NEW's EBITDA?
ENVUE MEDICAL INC NEW (FEED) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ENVUE MEDICAL INC NEW's gross margin?
ENVUE MEDICAL INC NEW (FEED) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ENVUE MEDICAL INC NEW's return on equity (ROE)?
ENVUE MEDICAL INC NEW (FEED) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ENVUE MEDICAL INC NEW's free cash flow?
ENVUE MEDICAL INC NEW (FEED) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ENVUE MEDICAL INC NEW's operating cash flow?
ENVUE MEDICAL INC NEW (FEED) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ENVUE MEDICAL INC NEW's total assets?
ENVUE MEDICAL INC NEW (FEED) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ENVUE MEDICAL INC NEW's capital expenditures?
ENVUE MEDICAL INC NEW (FEED) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ENVUE MEDICAL INC NEW spend on research and development?
ENVUE MEDICAL INC NEW (FEED) invested $1.8M in research and development during fiscal year 2025.
What is ENVUE MEDICAL INC NEW's current ratio?
ENVUE MEDICAL INC NEW (FEED) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is ENVUE MEDICAL INC NEW's liabilities-to-equity ratio?
ENVUE MEDICAL INC NEW (FEED) had a liabilities-to-equity ratio of 0.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is ENVUE MEDICAL INC NEW's return on assets (ROA)?
ENVUE MEDICAL INC NEW (FEED) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ENVUE MEDICAL INC NEW's P/E ratio?
ENVUE MEDICAL INC NEW (FEED) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $168K as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ENVUE MEDICAL INC NEW's price-to-sales ratio?
ENVUE MEDICAL INC NEW (FEED) trades at 0.1x sales, its market capitalization divided by $1.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $168K as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ENVUE MEDICAL INC NEW's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ENVUE MEDICAL INC NEW (FEED) held $4.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ENVUE MEDICAL INC NEW's Altman Z-Score?
ENVUE MEDICAL INC NEW (FEED) has an Altman Z-Score of -4.82, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ENVUE MEDICAL INC NEW's Piotroski F-Score?
ENVUE MEDICAL INC NEW (FEED) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ENVUE MEDICAL INC NEW's earnings high quality?
ENVUE MEDICAL INC NEW (FEED) reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.